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Abstract: Peripheral neuropathic pain arises from trauma to sensory nerves. Other types of 
acute neurotrauma such as stroke and spinal cord injury are treated immediately, largely to pre-
vent secondary damage. To pursue the possibility that neuropathic pain may also be amenable 
to early treatment, a rat model of neuropathic pain was induced using a 2-mm polyethylene 
cuff implanted around one sciatic nerve. Within 24 hours, hypersensitivity to von Frey hair 
stimulation appeared, as indicated by decreased paw withdrawal thresholds. When the cuff was 
removed 24 hours after implantation, readings returned to pre-implantation levels starting as 
early as day 18. When the cuff was removed after 4 days, there was a period of initial hyper-
sensitivity, and then an increase toward baseline at two time points near the end of the study; 
therefore, only a partial recovery toward pre-implantation values occurred. Having established 
that a temporal reversal can occur, the next step examined possible pharmacological reversal. 
The tachykinin NK1 receptor antagonist, CP-96,345, produced a minor increase in withdrawal 
thresholds in animals with the cuff left permanently implanted. To determine the effect of early 
and repeated administration of CP-96,345, it was given daily on days 1–4. The cuff was removed 
on day 4. Six days later, readings showed reversal of tactile hypersensitivity. We suggest that 
persistent neuropathic pain occurs from processes that develop over several hours and days, 
and that some of these processes may be prevented by early medical intervention. Thus, nerve 
injury in the context of chronic neuropathic pain should be treated in a similar manner to nerve 
injury resulting from stroke, spinal cord injury, and other types of neurotrauma. We suggest that 
effective medical intervention within the first few hours after nerve injury may spare a patient 
from a chronic debilitating pain that may be refractory to later therapies.
Keywords: neurotrauma, neuroplasticity, nerve injury, neuropathy, chronic pain, tactile 
hypersensitivity
Introduction
Neuropathic pain is noteworthy for its permanence and its relative resistance to medical 
treatment. As the effects of neurotrauma in other conditions can be at least partially 
reversible, we set out to determine whether the tactile hypersensitivity that develops 
in a rat model of peripheral neuropathic pain could be reversed physiologically. 
Following stroke, most patients undergo an immediate period of treatment, beginning 
within the first few hours, with the aim of restoring function.1–3 As soon as the 
symptoms of a stroke are recognized, pharmacotherapy, consisting of thrombolytic and 
neuroprotective agents, is started in order to minimize damage to neurons, limiting the 
biochemical cascade that leads to irreversible injury and cell death.4,5 Spinal cord injury 
is also treated immediately.6 Evidence suggests that there are primary and secondary Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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events that give rise to nerve cell death following spinal 
cord injury. Primary injury usually consists of spinal cord 
compression and the displacement and shock absorbed by the 
spinal cord.6 Secondary injury consists of the biochemical 
and molecular events that lead to cell death.6,7 Controlling 
the extent to which secondary injury occurs has a positive 
impact on patient outcome.6,7
The objective of the present study was to determine 
whether there might be a window of opportunity during which 
intervention might minimize or prevent the development 
of chronic tactile hypersensitivity in an animal model of 
neuropathic pain. Thus, the rationale for our study was 
to determine whether there may be a beneficial effect of 
removing the sciatic nerve cuff in the Mosconi and Kruger 
model,8 at various times after model induction. Ectopic 
activity in sensory fibers can be induced by irritation of the 
axons and it was rationalized, therefore, that by using the 
Mosconi and Kruger model of neuropathic pain, in which 
a polyethylene cuff is placed around the sciatic nerve, and 
removing the cuff at specific intervals after model induction, 
this would remove the peripheral irritation and possibly 
reverse or lessen the development of tactile hypersensitivity. 
When it became apparent that this reversal could take place, 
a study was done to investigate possible mechanisms leading 
to the irreversibility of the model, and the tachykinin NK1 
receptor antagonist, CP-96,345, was given during the onset 
phase of the model.
Materials and methods
Animals
Male Sprague-Dawley rats (Charles River, QC) were housed 
in pairs and maintained on a 12-hour light cycle, with food 
and water available ad libitum. All procedures complied 
with the “Guidelines for the Care and Use of Experimental 
Animals”, Volumes I and II, of the Canadian Council on 
Animal Care. All procedures were also approved by the 
University Council on Animal Care, University of Western 
Ontario (London, ON) and the Animal Research Ethics 
Board, McMaster University (Hamilton, ON). Rats used 
for the permanent, 1-day and 4-day cuff models weighed 
200–270 g on the day of cuff implantation. Rats used for the 
antagonist studies (in the permanent and 4-day cuff models) 
weighed 130–150 g on the day of cuff implantation.
Model induction
The method of inducing peripheral neuropathy was by 
implantation of a single cuff around the sciatic nerve, 
modified from the method described by Mosconi and 
Kruger,8 where two to four cuffs were used. Rats were 
anesthetized with a combination of ketamine (Ketalean; 
5 mg/100 g; Bimeda-MTC Animal Health, Inc, Cambridge, 
ON), xylazine (Rompun; 0.5 mg/100 g; Bayer HealthCare, 
Toronto, ON), and acepromazine (Atravet; 0.1 mg/100 g; 
Ayerst Veterinary Laboratories, Guelph, ON) given 
intraperitoneally (ip). The left sciatic nerve was exposed 
after blunt dissection of overlying muscle and freed from 
surrounding tissue. A cuff made of a 2-mm segment of 
polyethylene tubing (Intramedic PE-90; Clay Adams, 
Division of Becton Dickinson, Parsippany, NJ) slit 
longitudinally was fitted around the nerve. Subsequently, 
the muscle was sutured, and the skin closed using suture 
clips. Antibiotic ointment (Furacin, nitrofurazone 0.2%; 
Vetoquinol N-A, Inc; Lavaltrie, QC) was applied over 
the wound, and 0.03 mL of antibiotic (Tribrissen 24%, 
trimethoprim-sulfadiazine; Schering Canada, Inc, Pointe 
Claire, QC) was injected subcutaneously. Animals were 
placed under a heating lamp until they recovered from the 
anesthetic, and then returned to their home cages.
cuff removal
Animals were anesthetized and the sciatic nerve was exposed 
as described above. The cuff was located and then removed 
using fine forceps while care was taken not to damage the 
nerve. The muscle and skin were sutured as described above 
and the same postsurgical care procedures were followed. 
Cuff removal was done on either day 1 or day 4 after 
implantation.
Withdrawal threshold measurement
The testing chamber consisted of a 30 × 30 × 30 cm Plexiglas® 
box with a clear Plexiglas® floor. This floor contained 0.5-cm 
diameter holes that were spaced 1.5 cm apart, as described 
previously,9 and was positioned over an angled mirror that 
allowed an unobstructed view of the rat paws. Animals 
were placed in pairs in the testing chamber and allowed to 
acclimatize for 30 minutes prior to testing. Von Frey filaments 
(Stoelting Co, Wood Dale, IL) were applied to the soft tissue 
of the plantar surface of the hind paw to determine the 
withdrawal threshold. The first filament applied corresponded 
to a force of 2 g. If a negative response (no movement) was 
observed, a filament exerting greater force was then applied, 
and if a positive response (paw withdrawal) was observed, a 
filament of lesser force was applied next. Each filament was 
applied three times, at 3-second intervals. A 50% response Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
317
neuropathic pain
threshold was calculated according to the response pattern 
observed described by Chaplan et al.10 The maximum score 
possible was 15 g, and the minimum was 0.25 g.
Drugs
All drugs were administered ip at a volume of 0.1 mL/100 g 
body weight. CP-96,345 (tachykinin NK1 receptor antagonist; 
a gift from Pfizer Central Research, Groton, CT) was 
given at a dose of 5 mg/kg, dissolved in physiological 
saline. SR 48969 (NK2 receptor antagonist; a gift from 
Sanofi-Synthelabo, Montpellier, France) was given at a dose 
of 5 mg/kg dissolved in distilled water. SR 142801 (NK3 
receptor antagonist; a gift from Sanofi-Synthelabo) was 
given at a dose of 5 mg/kg and dissolved in 10% dimethyl 
sulfoxide (DMSO; Sigma-Aldrich, St Louis, MO) in distilled 
water. Postdrug testing was done 30 minutes after injection 
of each antagonist.
statistics
Data were analyzed using a repeated measures one-way 
analysis of variance (ANOVA) with the Bonferroni test 
for post hoc comparisons across days (Figures 1–3 and 5). 
Paired t-tests were used to compare pre- and postdrug 
  values on each testing day (Figures 4 and 5). Analyses were 
performed using Prism, GraphPad Software, Inc (v 4.03; 
San Diego, CA).
Results
effect of unilateral cuff implantation  
on withdrawal thresholds
Paw withdrawal thresholds were measured on days–2 and –1 
before surgery on day 0 and for up to 42 days after cuff 
implantation (n = 6; Figure 1). There was a significant decrease 
in withdrawal thresholds on all days after cuff implantation 
compared to pre-induction baseline values (all P , 0.01 
compared to days–2 and –1, with the exception of day–1 vs 
1, P , 0.05). No significant differences were observed for all 
pair-wise comparisons between each of the testing days after 
cuff implantation. Therefore, all values after cuff implantation 
were lower than pre-induction values, yet not different from 
each other. Contralateral paw withdrawal thresholds were not 
different before or after cuff implantation (data not shown). 
Sham surgeries were not preformed as this experiment serves 
as the control group for the subsequent cuff removal studies 
(Figures 2, 3, and 5). In an experiment where the cuff was 
implanted near, but not around the sciatic nerve, no effects on 
withdrawal thresholds were observed (data not shown).
effect of removing the cuff 24 hours  
after implantation
Paw withdrawal thresholds were measured on days–2 and –1 
before surgery on day 0 and for up to 42 days after cuff   
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Figure 1 Permanent cuff implantation. On day 0 rats (n = 6) were implanted with a 2-mm polyethylene cuff around the left sciatic nerve, which was kept in place for the 
duration of the study. Paw withdrawal thresholds were measured using von Frey filaments before and after model induction. There was a significant decrease in withdrawal 
thresholds after cuff implantation compared to pre-induction baseline values (days–2 and –1). no differences were observed between any of the testing days after cuff 
implantation. 
Notes: Values are shown as means ± standard error of the mean of the ipsilateral paw. *P , 0.05; ^P , 0.01; +P , 0.001 compared to pre-implantation values.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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implantation (n = 6; Figure 2). The cuff was removed on 
day 1. There was a significant decrease in withdrawal 
threshold on days 5 and 8 compared to pre-induction baseline 
values (days–2 and –1), all P , 0.01. Withdrawal thresholds 
on days 5 were significantly lower than those on days 20, 25, 
36, and 42 (all P , 0.05); day 8 was lower than days 25 and 42 
(P , 0.05). After this period of hypersensitivity, there was an 
increase in withdrawal thresholds, such that values observed 
starting at day 18 were not significantly different from pre-
implantation values. Thus withdrawal thresholds transiently 
decreased on days 5 and 8, with a return to pre-induction 
values as early as day 18. Contralateral paw withdrawal 
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Figure 2 One day cuff implantation. Rats (n = 6) were implanted with a cuff on day 0, and the cuff was removed on day 1. Paw withdrawal thresholds were measured using 
von Frey filament stimulation. There was a significant decrease in withdrawal thresholds on days 5 and 8 compared to pre-induction baseline values (^P , 0.01 compared to 
days–2 or –1). All subsequent values were not significantly different from pre-induction baselines. 
Note: Values are shown as means ± standard error of the mean of the ipsilateral paw.
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Figure 3 Four day cuff implantation. Rats (n = 7) were implanted with a cuff on day 0, and the cuff was removed on day 4. Paw withdrawal thresholds were measured using 
von Frey filament stimulation. There was a significant decrease in paw withdrawal thresholds after cuff implantation on most days compared to pre-induction baselines. 
Thresholds on days 25 and 28 were not significantly different from pre-induction baselines. 
Notes: Values are shown as means ± standard error of the mean of the ipsilateral paw. *P , 0.05; +P , 0.001 compared to pre-implantation values.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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thresholds after cuff implantation were not different from 
pre-implantation values (data not shown).
effect of removing the cuff 4 days  
after implantation
Paw withdrawal thresholds were measured on days–2 and –1   
before surgery on day 0 and for up to 42 days after cuff 
implantation (n = 7; Figure 3). The cuff was removed on 
day 4. There was a decrease in paw withdrawal threshold 
after cuff implantation compared to pre-induction baselines. 
With the exception of days 25 and 33, withdrawal thresholds 
were significantly lower on all days after cuff implantation 
compared to pre-induction baseline values (all P , 0.05 
compared to days–2 and –1). Values near the end of the 
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Figure 4 Tachykinin receptor antagonists. Rats (n = 6) were implanted with a cuff on day 0 and readings of withdrawal thresholds were measured on selected days over the 
next 39 days. Baseline readings were stable on all testing days starting on day 1 to day 39 (there were no significant differences and all values were significantly lower than 
pre-implantation levels; data not shown). The effect of the antagonists to the tachykinin nK1, nK2 and nK3 receptors were tested: cP-96,345 on days 6 and 21; sR 48968 on 
days 11 and 17; and SR 142801 on days 13 and 25, respectively. Withdrawal thresholds were significantly higher than pre-drug values after the administration of CP-96,345 
(on days 6 and 21; *P , 0.05) and sR 48968 (on day 17 only; *P , 0.05). 
Note: Values are shown as means ± standard error of the mean of the ipsilateral paw.
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Figure 5 Administration of a tachykinin nK1 receptor antagonist for 4 days in the 4-day cuff model. All rats (n = 4) were implanted with a cuff on day 0. each day, for 4 days 
after cuff implantation, withdrawal thresholds were measured before (closed circles) and 30 minutes after (open circles) administration of cP-96,345, an nK1 receptor 
antagonist; shaded area. The cuff was removed on day 4, and treatment with CP-96,345 was stopped. There were no significant differences between predrug baselines and 
postdrug values on days 1 to 4. Baseline withdrawal thresholds were measured up to day 25 postcuff implantation. Withdrawal thresholds on days 10 and 25 were significantly 
higher than values on days 1, 2, 3, and 4 (#P at least ,0.05). 
Note: Values are shown as means ± standard error of the mean of the ipsilateral paw.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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study, at days 25 and 33, were not significantly different 
from baseline values (days–2 and –1). Therefore, there was 
a partial recovery toward pre-induction values. Contralateral 
paw withdrawal thresholds were significantly lower than 
pre-implantation values only on day 8 (P , 0.05 compared 
to day–2 or –1; data not shown).
effect of tachykinin receptor antagonists 
in permanently-implanted rats
Rats (n = 7) were implanted with a cuff on day 0 and withdrawal 
thresholds were measured across a 39-day observation period. 
One rat was removed from the study after day 13 (and all 
previous values were omitted from the analysis) because 
the ipsilateral paw did not show the typical signs of model 
induction (curled toes, redness, guarding, overgrown nails). 
As seen in Figure 1, there was a significant decrease in 
withdrawal thresholds after cuff implantation, which persisted 
for at least 39 days (day–1 versus each testing day, P , 0.001; 
n = 6; data not shown). Tachykinin receptor antagonists were 
given on the following days: CP-96,345 (NK1) on days 6 and 
21; SR 48968 (NK2) on days 11 and 17; and SR 142801 (NK3) 
on days 13 and 25. Withdrawal thresholds were measured 
before and after drug administration (Figure 4). Withdrawal 
thresholds were significantly higher than predrug values after 
the administration of CP-96,345 (on both days tested, 6 and 
21) and SR 48968 (on day 17 only); all P , 0.05. No effect 
of SR 48968 was observed on day 11, and there were no 
effects of SR 142801 on testing day, 13 or 25. The antagonists 
did not have any effect on the contralateral paw, or on naïve 
rats (data not shown). Administration of the antagonists did 
not have an effect on the progression of the permanent cuff 
model, as no significant differences were observed for all 
pair-wise comparisons between each of the testing days after 
cuff implantation (data not shown).
effect of the nK1 receptor antagonist  
on development of hypersensitivity
Given that CP-96,345 had the most consistent effect 
(Figure 4), it was used to determine if early, repeated 
administration of this antagonist would have an effect 
on the development of hypersensitivity in this model of 
peripheral neuropathy. Figure 5 shows the withdrawal 
thresholds of the ipsilateral paw of rats (n = 4) that had a 
cuff implanted on day 0 and removed on day 4. Rats were 
treated daily on days 1 to 4 with CP-96,345. There were no 
significant differences between pre- and postdrug values on 
days 1 to 4. Baseline withdrawal thresholds were measured 
after cuff removal and drug administration was stopped, up 
to day 25 after cuff implantation. A repeated measures one-
way ANOVA of baseline readings showed that withdrawal 
thresholds on day 10 were significantly higher than values 
on days 1 (P , 0.05), 2, 3 (P , 0.01), and 4 (P , 0.05). 
Values on day 25 were also significantly higher than values 
on days 1 (P , 0.05), 2 (P , 0.01), 3 (P , 0.001), and 4 
(P , 0.05).
Discussion
These results demonstrate that the tactile hypersensitivity 
in an animal model of neuropathic pain can be reversed 
physiologically, by removing the source of the irritation to the 
sciatic nerve. It was found that while removal of the cuff at 
24 hours after model induction led to full recovery to baseline 
values, if the cuff was removed after 4 days there was also a 
trend toward recovery, but it was not fully achieved.
The fact that removal of the cuff at 4 days resulted in only 
partial recovery suggests that the presence of the cuff set in 
place mechanisms that persist even after the source of the 
nerve irritation is no longer present. This suggests further that 
there is a difference between a short-term and a long-term 
irritation or injury to the nerve in terms of hypersensitivity 
to tactile stimulation to the peripheral receptive fields. Thus, 
there remains a “shadow” hypersensitivity when the cuff is 
removed after 4 days.
Full recovery occurred with removal of the cuff at 
24 hours, in contrast to the partial recovery observed when 
the cuff was removed after 4 days. This suggests that the time 
of removal of the irritant condition is critical, and prompts 
the hypothesis that there may be an optimal window of time 
during which intervention may reduce and even prevent the 
development of a chronic tactile hypersensitivity, and that 
in humans there may be a window of time for effective 
therapeutic intervention to prevent the development of a 
persistent neuropathic pain. This may be a critical issue 
in view of the relative resistance of this type of pain in 
humans.
As it has been established that substance P is an important 
neuromodulator involved in the transmission of pain, the 
effects of antagonists to the receptors at which substance 
P acts were tested. Antagonists to the tachykinin NK1, 
NK2, and NK3 receptors were administered to rats with a 
permanent cuff. CP-96,345 (the NK1 receptor antagonist) 
significantly increased withdrawal thresholds on both days 
tested, ie, on days 6 and 21 after cuff implantation. The effect 
was modest, as withdrawal thresholds remained below 5 g. 
SR 48968, the NK2 receptor antagonist, also had a marginal 
effect, but only on day 17, not on day 11. These results Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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indicate that substance P may be involved in the maintenance 
phase of neuropathic pain, similar to a report by Cahill and   
Coderre.11
In view of the observation that CP-96,345 had the 
most consistent effect, it was used to investigate possible 
mechanisms underlying the full versus partial reversibility 
of the model. The rationale for selecting this approach 
was that if it proved to be effective this might provide an 
avenue to explore a therapeutic approach to prevent or limit 
the development of neuropathic pain following peripheral 
nerve damage. Thus, in rats in which the cuff was to be 
removed 4 days after implantation, the antagonist was given 
starting 1 day after model induction and continuing daily until 
the cuff was removed at day 4. During this period there was 
a tendency for the readings 30 minutes after administration 
to be numerically higher (though not significant statistically) 
than those taken just before administration, possibly 
suggesting that a process is occurring in which NK1 receptors 
are involved in the induction of a state of hypersensitivity, 
particularly during the earliest days. Interestingly, the relative 
lack of an acute effect of CP-96,345 on day 4 suggests that 
other mechanisms may have begun to be recruited by this 
time. Intervention by early and repeated administration of 
the NK1 receptor antagonist facilitated recovery of the 4-day 
cuff model, within 6 days of the end of drug treatment. This 
supports the hypothesis that there may be a window of time 
during which the development of chronic pain may be pre-
vented, and indicates that NK1 receptors may be intimately 
involved in establishing the permanence of hypersensitivity 
in this animal model of peripheral neuropathic pain. The data 
also support the concept that treatment for neuropathic pain 
should begin before the onset of symptoms whenever any 
damage to a nerve occurs or is suspected. Early, aggressive 
treatment with an appropriate drug may reduce the incidence 
or severity of the ensuing neuropathic pain.
Evidence from other types of trauma to the nervous 
system indicates that early treatment is of critical importance 
in determining outcome. Following a stroke, it is believed that 
the adequacy of treatment given in the first 24 to 48 hours 
is the most important factor for optimal outcome.4,12–15 
Antithrombolytic medication to reestablish circulation to 
the affected areas of the central nervous system and thus 
to reduce secondary effects of the stroke, is effective only 
if given within 3 hours following the stroke.14,16 The onset 
of irreversible damage depends greatly on the duration and 
severity of ischemia.4 Neuroprotective agents are typically 
administered after a stroke to increase the resistance of the 
brain to ischemic damage.2,4,12
Following spinal cord injury, it is also standard procedure 
to attempt to reestablish function through early treatment.7 
Evidence from basic science animal studies as well as from 
clinical studies suggests an overall positive clinical benefit of 
early surgical intervention.17 In the case of humans, surgical 
intervention often consists of stabilizing the spinal column to 
prevent further damage.6 However, acute spinal cord injury 
involves primary and secondary mechanisms of injury.18 
While efforts are taken to reduce primary injury,19,20 steps 
are also taken to prevent the secondary injury resulting from 
changes in the tissues and the circulation.6,21
In the animal model of neuropathic pain used in this 
study, the presence of the sciatic nerve cuff appears to 
initiate processes that are fully reversible if the primary 
source of the injury is removed within 24 hours. However, 
these processes are only partially reversible if the primary 
injury is allowed to last for 4 days. In this case, the cuff leads 
to changes that persist even in its absence. As the onset of 
secondary mechanisms is a function of the duration of the 
injury, the establishment of neuropathic pain may be viewed 
as a degenerative process. The antagonist studies show that 
NK1 receptors may be involved in this degenerative process 
that gives rise to hypersensitivity to tactile stimulation, which 
is characteristic of this neuropathic pain model.
These results suggest that peripheral drive may be playing 
a governing role in neuropathic pain, as suggested recently.22 
Spontaneous discharge in sensory fibers in models of peripheral 
neuropathy has been proposed in a number of models. Several 
studies have reported that systemic administration of lidocaine 
decreases ectopic activity recorded from injured peripheral 
sensory fibers.23–26 Furthermore, systematic reviews of human 
studies using systemic administration of local anesthetic 
drugs support their use for neuropathic pain.27,28 A governing 
role of afferent drive is also reflected in the data of Kim and 
Chung29 where nerve block transiently reversed the behavioral 
hypersensitivity to tactile stimulation. A predominant role of 
peripheral drive may also be reflected in a study by Sun and 
colleagues,30 who found that ectopic discharges in injured 
sensory nerves were highly correlated with hypersensitivity in 
the first 24 hours after spinal nerve ligation, and they suggest 
that ectopic discharge may be triggering neuropathic pain. 
The development of thermal and tactile hypersensitivity is 
permanently inhibited if spontaneous afferent activity is blocked 
immediately after nerve injury (for at least 3–5 days), again 
pointing to early spontaneous afferent activity as a trigger for 
pain behaviors.31 It is also interesting to note that previous 
studies have used the chronic constriction model of neuropathic 
pain, followed by decompression (removal of the ligatures) at Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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postoperative week 4. At 8 weeks, they observed a reversal of 
thermal hyperalgesia and mechanical allodynia,32–34 an increase 
in the skin innervation index of substance P,33 an increase to 
normal levels of substance P and the δ-opioid receptor in the 
dorsal horn,34 and a decrease to normal levels of extracellular 
signal-regulated kinase (ERK) activation in the dorsal horn.32
In conclusion, these studies and our present data suggest 
that upon peripheral nerve injury a window of opportunity 
for effective medical intervention may be open, and, as 
time passes, the window closes progressively until, at 
some point, it is shut and the pain is entrenched as chronic 
neuropathic pain. In our model, full, spontaneous reversal 
with cuff removal after 24 hours but not after 4 days, and 
pharmacological reversal with cuff removal after 4 days, 
suggests that medical intervention may have a window of 
opportunity for effective treatment. We therefore suggest that 
the onset of chronic neuropathic pain is a process that occurs 
over several hours and days, and that effective intervention 
within the first few hours after nerve injury may spare a 
patient from a chronic debilitating neuropathic pain that may 
be refractory to later therapeutic interventions.
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